Inhibition of Glycolysis Suppresses Cell Proliferation and Tumor Progression In Vivo: Perspectives for Chronotherapy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Apr 2021
Historique:
received: 23 03 2021
revised: 16 04 2021
accepted: 20 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 15 5 2021
Statut: epublish

Résumé

A high rate of glycolysis is considered a hallmark of tumor progression and is caused by overexpression of the enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3). Therefore, we analyzed the possibility of inhibiting tumor and endothelial cell metabolism through the inhibition of PFKFB3 by a small molecule, (

Identifiants

pubmed: 33922320
pii: ijms22094390
doi: 10.3390/ijms22094390
pmc: PMC8122821
pii:
doi:

Substances chimiques

PFK15 0
Pyridines 0
Quinolines 0
PFKFB3 protein, human EC 2.7.1.105
Phosphofructokinase-2 EC 2.7.1.105
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Slovak Research and Development Agency
ID : APVV-17-0178
Organisme : Slovak Research and Development Agency
ID : APVV-16-0209
Organisme : Research and Development Operational Programme funded by the ERDF
ID : ITMS 26240220086
Organisme : Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic
ID : VEGA 2/0050/19

Références

Mol Med Rep. 2008 Jul-Aug;1(4):599-603
pubmed: 21479457
PLoS One. 2016 Sep 26;11(9):e0163768
pubmed: 27669567
J Biol Chem. 2011 Dec 2;286(48):41600-41615
pubmed: 21862591
Br J Cancer. 2002 Aug 27;87(5):555-61
pubmed: 12189556
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Cell Metab. 2013 Nov 5;18(5):634-47
pubmed: 23973331
Nature. 2002 Oct 17;419(6908):729-34
pubmed: 12384701
Mol Cell Biochem. 2018 Aug;445(1-2):123-134
pubmed: 29327288
Pathol Res Pract. 1993 Sep;189(8):862-6
pubmed: 8302707
J Mol Biol. 2020 May 29;432(12):3680-3699
pubmed: 31996313
Nucleic Acids Res. 2009 Apr;37(6):e45
pubmed: 19237396
PeerJ. 2018 Jan 31;6:e4327
pubmed: 29404219
Nat Rev Mol Cell Biol. 2019 Apr;20(4):227-241
pubmed: 30635659
Pharmacol Res. 2019 Dec;150:104511
pubmed: 31678210
Signal Transduct Target Ther. 2017 Nov 24;2:17044
pubmed: 29263928
Mol Cancer Ther. 2008 Jan;7(1):110-20
pubmed: 18202014
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Biol Cell. 1995 Apr;6(4):387-400
pubmed: 7626805
PLoS One. 2019 Oct 28;14(10):e0224396
pubmed: 31658284
Int J Cancer. 2019 Jan 1;144(1):178-189
pubmed: 30226266
Cancer Metab. 2020 Apr 2;8:2
pubmed: 32266066
Mol Pharmacol. 2008 Jan;73(1):128-36
pubmed: 18094076
Mol Cancer Ther. 2013 Aug;12(8):1461-70
pubmed: 23674815
Int J Mol Med. 2018 Jul;42(1):359-367
pubmed: 29620138
Nat Med. 2018 Dec;24(12):1795-1803
pubmed: 30523327
Med Res Rev. 2019 Jan;39(1):70-113
pubmed: 29785785
Trends Cancer. 2019 Aug;5(8):475-494
pubmed: 31421905
PLoS One. 2014 Aug 06;9(8):e102776
pubmed: 25099274
Eur J Med Chem. 2020 Oct 1;203:112612
pubmed: 32679452
Biomed Res Int. 2014;2014:295760
pubmed: 25114899
PLoS One. 2015 Mar 25;10(3):e0121561
pubmed: 25806512
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Gen Physiol Biophys. 2019 Mar;38(2):157-163
pubmed: 30821250
Nat Cell Biol. 2015 Oct;17(10):1304-16
pubmed: 26322680
Trends Endocrinol Metab. 2019 Jul;30(7):445-458
pubmed: 31155396
Eur J Med Chem. 2016 Feb 15;109:314-41
pubmed: 26807863
J Virol. 1999 Jun;73(6):4983-90
pubmed: 10233960
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Pathol. 1998 Jul;51(7):506-11
pubmed: 9797726
Biomed Pharmacother. 2017 Nov;95:1225-1231
pubmed: 28931215
Sci Rep. 2016 Apr 15;6:24324
pubmed: 27079271
Int J Mol Sci. 2019 May 01;20(9):
pubmed: 31052469
Breast Cancer Res Treat. 2009 Sep;117(2):423-31
pubmed: 18651214
Anticancer Res. 2016 Apr;36(4):1479-88
pubmed: 27069123
Int J Oncol. 2018 Mar;52(3):945-954
pubmed: 29393396
Cell Physiol Biochem. 2017;44(2):763-777
pubmed: 29169174
Oncol Res. 2014;22(3):147-57
pubmed: 26168133
Cell Cycle. 2015;14(21):3379-88
pubmed: 26431254
Int J Mol Sci. 2018 Jan 23;19(2):
pubmed: 29360760

Auteurs

Jana Horváthová (J)

Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovicova 6, 842 15 Bratislava, Slovakia.

Roman Moravčík (R)

Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovicova 6, 842 15 Bratislava, Slovakia.

Miroslava Matúšková (M)

Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovakia.

Vladimír Šišovský (V)

Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava, University Hospital Bratislava, Sasinkova 4, 811 08 Bratislava, Slovakia.

Andrej Boháč (A)

Department of Organic Chemistry, Faculty of Natural Sciences, Comenius University in Bratislava, 842 15 Bratislava, Slovakia.

Michal Zeman (M)

Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovicova 6, 842 15 Bratislava, Slovakia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH